Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 7,915Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Alliance revenue - Lynparza

02 14Lynparza

PharmaCompass

01

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,776

2019 Revenue in Millions : 1,198

Growth (%) : 48

blank

02

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 2,348

2020 Revenue in Millions : 1,776

Growth (%) : 32

blank

03

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 725

2019 Revenue in Millions : 444

Growth (%) : 63

blank

04

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 989

2020 Revenue in Millions : 725

Growth (%) : 36

blank

05

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,116

2021 Revenue in Millions : 989

Growth (%) : 13

blank

06

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 2,638

2021 Revenue in Millions : 2,348

Growth (%) : 12

blank

07

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 2,811

2022 Revenue in Millions : 2,638

Growth (%) : 7

blank

08

Brand Name : Alliance revenue - Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Alliance revenue - Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,199

2022 Revenue in Millions : 1,116

Growth (%) : 7

blank

09

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 94

Growth (%) : New Launch

blank

10

Brand Name : Lynparza

Olaparib

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Lynparza

arrow
2024 ACI Convention
Not Confirmed

Olaparib

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 297

2016 Revenue in Millions : 218

Growth (%) : 36

blank